Breaking News Headlines Today | Ground News

See every side of every news story

Healio image

News from Healio

Healio’s media bias is Center. Ground News assigned this score by aggregating media bias ratings of a Center rating from Ad Fontes Media .

Healio’s factuality rating is Very High. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Healio

Where is Healio located?Healio's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byAd Fontes Media

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Healio News

Senate rejects dueling health care bills as Obamacare deadline nears — REUTERS / pwu404

Obamacare · United States

Senate rejects dueling health care bills as Obamacare deadline nears

53% Center coverage: 216 sources

The Senate rejected dueling health care bills Thursday, all but guaranteeing that Obamacare subsidies used by more than 20 million Americans will lapse at the end of the year.See the Story

Federal judge throws out Trump order blocking development of wind energy — REUTERS / FES376

US Politics · United States

Federal judge throws out Trump order blocking development of wind energy

42% Center coverage: 74 sources

A federal judge on Monday struck down President Donald Trump’s executive order blocking wind energy projects, saying the effort to halt virtually all leasing of wind farms on federal lands and waters was “arbitrary and capricious” and violates U.S. law.See the Story

Five-Day Azacitidine Best Among Shorter Hypomethylating Agent Regimens for Low-Risk MDS

United States · United States

Five-Day Azacitidine Best Among Shorter Hypomethylating Agent Regimens for Low-Risk MDS

45% Center coverage: 9 sources

ORLANDO — A decade-long investigation of shorter regimens of hypomethylating agents for low-risk myelodysplastic syndrome revealed a 5-day course of azacitidine significantly improved survival compared with 3-day azacitidine and decitabine.The results, presented at ASH Annual Meeting and Exposition, showed 5-day azacitidine improved EFS and OS with no early deaths or new safety signals.See the Story

Breaking News Topics Related to Healio